Education
About Us
Working with TipRanks
Follow Us
Immatics N.V. (IMTX)
:IMTX
IMTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.88 - $13.77
Previous CloseN/A
Volume408.80K
Average Volume (3M)820.26K
Market Cap
$486.20M
Enterprise Value$256.88M
Total Cash (Recent Filing)€236.75M
Total Debt (Recent Filing)€16.20M
Price to Earnings (P/E)51.7
Beta1.07
Next Earnings
May 20, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding121,550,170
10 Day Avg. Volume1,067,629
30 Day Avg. Volume820,260
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.75
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$15.50Price Target Upside271.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Immatics News
PremiumCompany Announcements
Immatics Reports Strong 2024 Financial Results and Progress
PremiumCompany Announcements
Immatics Advances PRAME Cell Therapy and Expands Oncology Pipeline
PremiumCompany Announcements
Immatics Faces Termination of Key Collaboration with Bristol Myers Squibb---
Bulls Say, Bears Say
Bulls Say
Clinical DataImpressive data was reported for IMA203, with a 62% overall response rate and a 92% disease control rate in a heavily pre-treated metastatic melanoma patient group.
Financial PositionIMTX ended 4Q24 with $628.0M in cash and equivalents, providing a cash runway into 2H27.
PartnershipsImmatics N.V. continues to have ongoing partnerships with Editas Medicine and Moderna Therapeutics, which investors may view as an important source of external validation.
Pipeline ProgressIMTX confirmed that the Phase III SUPRAME study evaluating IMA203 in cutaneous melanoma has started to enroll patients and remains on track to complete enrollment by the end of 2026.
Bears Say
Collaboration TerminationThe termination by Bristol Myers Squibb of a collaboration with Immatics N.V. is seen as an incremental negative for the stock.
Equity FinancingIMTX shares dropped 16%, suspected to be related to the surprising decision to announce an equity financing.
---
Ownership Overview
―
Insiders
12.36% Mutual Funds
57.04% Other Institutional Investors
30.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMTX FAQ
What was Immatics N.V.’s price range in the past 12 months?
Immatics N.V. lowest stock price was $3.88 and its highest was $13.77 in the past 12 months.
What is Immatics N.V.’s market cap?
Immatics N.V.’s market cap is $486.20M.
When is Immatics N.V.’s upcoming earnings report date?
Immatics N.V.’s upcoming earnings report date is May 20, 2025 which is in 47 days.
How were Immatics N.V.’s earnings last quarter?
Immatics N.V. released its earnings results on Mar 27, 2025. The company reported $0.502 earnings per share for the quarter, beating the consensus estimate of -$0.322 by $0.824.
Is Immatics N.V. overvalued?
According to Wall Street analysts Immatics N.V.’s price is currently Undervalued.
Does Immatics N.V. pay dividends?
Immatics N.V. does not currently pay dividends.
What is Immatics N.V.’s EPS estimate?
Immatics N.V.’s EPS estimate is -0.3.
How many shares outstanding does Immatics N.V. have?
Immatics N.V. has 121,550,170 shares outstanding.
What happened to Immatics N.V.’s price movement after its last earnings report?
Immatics N.V. reported an EPS of $0.502 in its last earnings report, beating expectations of -$0.322. Following the earnings report the stock price went up 3.974%.
Which hedge fund is a major shareholder of Immatics N.V.?
Currently, no hedge funds are holding shares in IMTX
---
Immatics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (271.70% Upside)
$15.50 (271.70% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.13%
12-Months-Change
Fundamentals
Return on Equity
3.73%
Trailing 12-Months
Asset Growth
27.96%
Trailing 12-Months
Company Description
Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
---
IMTX Stock 12 Month Forecast
Average Price Target
$15.50
▲(271.70% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering IMTX
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-22.71%
reiterated a buy rating 4 months ago
Copying Graig Suvannavejh's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -22.71% per trade.
---